Holen Sie sich die Stockscreener-App
31.68
1.34%
-0.43
Handel nachbörslich:
31.50
-0.18
-0.57%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Precision Trading with Capricor Therapeutics Inc. (CAPR) Risk Zones - Stock Traders Daily
Capricor Therapeutics (CAPR) Is Up 7.2% After HOPE-3 Data And PDUFA Update Has The Bull Case Changed? - Sahm
Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone - Sahm
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock - marketbeat.com
Capricor Therapeutics (CAPR) director sells 7,529 exercised shares - stocktitan.net
Capricor Therapeutics (CAPR) reports positive phase 3 HOPE-3 data and $318M 2025 cash balance - MSN
Option exercise and 10b5-1 sales reported by CAPR (NASDAQ: CAPR) - stocktitan.net
Capricor Therapeutics (NASDAQ:CAPR) Trading Up 6.6%Here's Why - marketbeat.com
Karimah Es Sabar Sells 61,265 Shares of Capricor Therapeutics (NASDAQ:CAPR) Stock - marketbeat.com
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells $1,667,397.05 in Stock - marketbeat.com
Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) CFO Sells 25,000 Shares of Stock - marketbeat.com
CAPR SEC FilingsCapricor Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Capricor Therapeutics(CAPR.US) Director Sells US$3.52 Million in Common Stock - Moomoo
Capricor Therapeutics EVP Krasney sells $752k in shares By Investing.com - Investing.com Canada
Capricor Therapeutics director sells $3.5m in shares - Investing.com UK
Capricor Therapeutics director sells $3.5m in shares By Investing.com - Investing.com Australia
Capricor (NASDAQ: CAPR) CFO sells 25K shares after option exercise - stocktitan.net
Director at Capricor (NASDAQ: CAPR) sells 115,000 shares via 10b5-1 plan - stocktitan.net
CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval - MSN
Capricor Therapeutics stock jumps as FDA resumes Deramiocel review - MSN
Capricor Therapeutics (NASDAQ: CAPR) proxy: Board nominees, pay and Nippon Shinyaku deals - stocktitan.net
[144] CAPRICOR THERAPEUTICS, INC. SEC Filing - Stock Titan
Capricor Therapeutics Stock Rises Above 50-Day Average - National Today
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving AverageWhat's Next? - marketbeat.com
Insider Sell: Is Capricor Therapeutics Inc stock a good dividend stock2026 Price Momentum & Safe Capital Preservation Plans - baoquankhu1.vn
Value Recap: Is Capricor Therapeutics Inc a defensive stock2026 Levels & Weekly High Potential Stock Alerts - baoquankhu1.vn
Is Capricor Therapeutics Inc stock a good dividend stock2026 Retail Activity & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Capricor (CAPR) EVP and General Counsel exercises options for 2,500 shares - stocktitan.net
Bull Run: Does Capricor Therapeutics Inc stock benefit from AI growth2026 Support & Resistance & Real-Time Sentiment Analysis - baoquankhu1.vn
Momentum Shift: Is AKAM a top pick in the sectorTreasury Yields & Comprehensive Market Scan Reports - baoquankhu1.vn
Merger Talk: How does Capricor Therapeutics Inc perform in inflationary periods2026 Opening Moves & Safe Entry Trade Reports - baoquankhu1.vn
Capricor Therapeutics Opens with 10.29% Gain, Outperforming S&P 500's 0.83% Rise - Markets Mojo
Technical Reactions to CAPR Trends in Macro Strategies - Stock Traders Daily
CAPR Technical Analysis | Trend, Signals & Chart Patterns | CAPRICOR THERAPEUTICS INC (NASDAQ:CAPR) - ChartMill
Capricor Therapeutics Tokenized Stock (Ondo) price today, CAPRon to USD live price, marketcap and chart - CoinMarketCap
Capricor Therapeutics, Inc.(NasdaqGS:CAPR) added to S&P Biotechnology Select Industry Index - marketscreener.com
Q4 2025 Capricor Therapeutics Inc Earnings Call Transcript - GuruFocus
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Moderate Buy" from Analysts - marketbeat.com
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
Why Capricor Therapeutics (CAPR) Is Down 8.0% After FDA Resumes Deramiocel Review And Phase 3 Update - Sahm
Growth Review: Is Capricor Therapeutics Inc a defensive stock2026 EndofYear Setup & Long-Term Safe Return Strategies - baoquankhu1.vn
Capricor Therapeutics Pipeline Overview: Deramiocel for Muscular Dystrophy and Exosome-Based Vaccine Development (2025-2026) - Minichart
Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insight - GuruFocus
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 - 富途牛牛
Decoding Capricor Therapeutics Inc (CAPR): A Strategic SWOT Insi - GuruFocus
Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash Balance - Insider Monkey
Capricor Therapeutics 2025 10-K: Revenue $0, EPS $(2.26) - TradingView
Deramiocel DMD program and big Nippon Shinyaku deals at Capricor (NASDAQ: CAPR) - Stock Titan
About Capricor Therapeutics (Ondo Tokenized) - Coinbase
13 Best Hot Stocks to Buy According to Analysts - Insider Monkey
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2025 Earnings Call Transcript - Insider Monkey
A Look At Capricor Therapeutics’ (CAPR) Valuation After FDA Resumes Deramiocel Review On New HOPE-3 Data - Sahm
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):